Efficacy of elbasvir/grazoprevir in treatment of genotype 1 chronic hepatitis C: A real-world study
DOI:10.3969/j.issn.1001-5256.2020.12.012
- VernacularTitle:艾尔巴韦/格拉瑞韦治疗基因1型慢性丙型肝炎效果的真实世界研究
- Author:
Yang XIA
1
;
Jing HUANG
;
Shuduo WU
;
Jianping LI
;
Wenli CHEN
;
Zhiwei XIE
;
Yujuan GUAN
Author Information
1. Department of Hepatology, Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou 510060, China
- Publication Type:Research Article
- Keywords:
hepatitis C, chronic;
antiviral agents;
therapeutics
- From:
Journal of Clinical Hepatology
2020;36(12):2700-2704
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the efficacy and safety of elbasvir/grazoprevir in patients with genotype 1 hepatitis C in the real world. MethodsA total of 35 patients with hepatitis C who received elbasvir/grazoprevir treatment in Guangzhou Eighth People’s Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, and Guangdong General Hospital from August 2018 to March 2019 were enrolled, treated for 12 weeks, and then followed up for 12 weeks after drug withdrawal. The patients were observed in terms of sustained virologic response at week 12 after drug withdrawal (SVR12), biochemical response, and incidence rate of adverse events during treatment and follow-up. The Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between groups, and the Mann-Whitney U test was used for further comparison between two groups; the chi-square test was used for comparison of categorical data between groups. A logistic regression analysis was used to investigate the risk factors for virologic response in patients with hepatitis C. ResultsAmong the 35 patients with HCV infection, 97.1% (34/35) had genotype 1b HCV and 2.9% (1/35) had genotype 1a HCV; of all patients, 28 (80%) were non-cirrhotic patients with chronic hepatitis C and 7 (20%) had compensated liver cirrhosis. At the end of treatment, the virologic response rate of 100% (28/28) and SVR12 was 94.74% (18/19). In addition, age, sex, baseline HCV RNA load, previous treatment history, presence or absence of liver cirrhosis, renal function, and presence or absence of other diseases did not affect the treatment outcome (all P＞0.05). There were significant changes in the levels of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, and albumin from baseline to the end of 12-week treatment (Z=-7.131, -6.797, -3.060, and -2.875, all P＜0.05). No patient experienced drug withdrawal during treatment. ConclusionThis study confirms that elbasvir/grazoprevir has good efficacy and safety in the treatment of hepatitis C in domestic real-world studies.
